Clinical Trial

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Study acronym: TOP-FLOR
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
First line treatment with combination rituximab and golcadomide with, or without nivolumab, in patients in previously untreated Follicular Lymphoma
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-03-15; most recent amendment 2025-08-18.
Status change: Recruiting → Active, Not Recruiting 2025-08-18
Status change: Not Yet Recruiting → Recruiting 2023-08-30
Trial Details
NCT Number NCT05788081
Lead Sponsor Olivia Newton-John Cancer Research Institute
Collaborators: Austin Health, Grampians Health, Fiona Stanley Hospital, Eastern Health, Barwon Health, Bristol-Myers Squibb
Conditions Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV
Enrollment 40 participants
Start Date 2023-08-31
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-20